adagrasib
Not Tagged
['import']
#asco22 starts with an important paper concomitantly. this reinforces the dominance of precision oncology in the landscape. rr 43%, dor 8,5m, os 12,6m. 75% &gt; 50% reduction in size. pretty good. noteworthy: 86% former smokers and +1l previously. 
Editor: Marcos André Costa. Oncologist, Sao Paolo????. Head Brazilian Precision Oncology Group. ASCO/AACR member. Tweets are my own. Armenian roots ????.